Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other
✍️ Advertorial Desk, .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow, Class, Wp-Block-Co-Authors-Plus, Display Inline, .Wp-Block-Co-Authors-Plus-Avatar, Where Img, Height Auto Max-Width, Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar, Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright📅 February 28, 2025 12:00 AM🕐 Scraped: November 17, 2025
Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis
Interim safety and pharmacokinetic data from healthy volunteers anticipated in 2H 2025
BOSTON, Feb. 28, 2025 /PRNewswire/ — Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced the initiation of dosing in healthy volunteers (HV) in
📰
Continue Reading on Laotian Times
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.
